460 related articles for article (PubMed ID: 11579708)
1. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
2. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
3. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
[TBL] [Abstract][Full Text] [Related]
4. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
5. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years.
Bettoni L; Geri A; Airò P; Danieli E; Cavazzana I; Antonioli C; Chiesa L; Franceschini F; Grottolo A; Zambruni A; Radaeli E; Cattaneo R
Clin Rheumatol; 2002 Jun; 21(3):244-50. PubMed ID: 12111631
[TBL] [Abstract][Full Text] [Related]
6. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
[TBL] [Abstract][Full Text] [Related]
7. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
[TBL] [Abstract][Full Text] [Related]
8. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
[TBL] [Abstract][Full Text] [Related]
9. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
12. [Iloprost for the treatment of systemic sclerosis].
Hachulla E; Launay D; Hatron PY
Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group.
Airò P; Rossi M; Scarsi M; Danieli E; Grottolo A; Zambruni A
Clin Exp Rheumatol; 2007; 25(5):722-7. PubMed ID: 18078620
[TBL] [Abstract][Full Text] [Related]
14. Is iloprost effective in secondary Raynaud's phenomenon?
Lustig N; Rada G
Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
[TBL] [Abstract][Full Text] [Related]
15. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
[TBL] [Abstract][Full Text] [Related]
16. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
[TBL] [Abstract][Full Text] [Related]
17. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
Black CM; Halkier-Sørensen L; Belch JJ; Ullman S; Madhok R; Smit AJ; Banga JD; Watson HR
Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
[TBL] [Abstract][Full Text] [Related]
18. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Balbir-Gurman A; Braun-Moscovici Y; Livshitz V; Schapira D; Markovits D; Rozin A; Boikaner T; Nahir AM
Clin Rheumatol; 2007 Sep; 26(9):1517-21. PubMed ID: 17401513
[TBL] [Abstract][Full Text] [Related]
20. Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine.
Della Bella S; Molteni M; Mascagni B; Zulian C; Compasso S; Scorza R
Clin Exp Rheumatol; 1997; 15(2):135-41. PubMed ID: 9196864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]